TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7954244
Drug: Low vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vs. Intermediate dose
Study: 2790695
Drug: Endocrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine treatment (tamoxifen [T], 40 mg daily for 3 years)
Study: 26742306
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera syrup (10 mL/d, standardized to 5.0 mg polysaccharide per mL)
Study: 26742306
Drug: Omeprazole capsule
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole capsule (20 g/d)
Study: 26742306
Drug: Ranitidine tablet
Normalized name: Ranitidine Tablets
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine tablet (150 mg in a fasted state in the morning and 150 mg 30 min before sleep at night)
Study: 19743936
Drug: 2.5% chitin‐glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% chitin‐glucan formulation
Study: 16061111
Drug: Amoxicillin-sulbactam (Ax/S)
Normalized name: amoxicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-sulbactam (Ax/S) at a dosage of 80 mg/(kg day), b.i.d. for 10 days
Study: 9762567
Drug: Dihydroartemisinin produced
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin produced in Vietnam but formulated by the Government Pharmaceutical Organization of Thailand
Study: 9762567
Drug: Dihydroartemisinin produced
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin produced and formulated by the Government Pharmaceutical Organization of Thailand
Study: 7871074
Drug: Alcohol and
Normalized name: Polyvinyl alcohol and povidone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol and marijuana in combination
Study: 25947566
Drug: Elisidepsin (PM02734)
Normalized name: PM02734
DrugBank: PM02734 (DB05158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elisidepsin (PM02734) administered as a 30-min intravenous infusion every 3 weeks (q3wk) at doses ranging from 0.1 to 1.6 mg/m(2)
Study: 19919789
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis (AP) administered 2 hours before incision and continued for 24 hours (Experimental Group, EG)
Study: 19919789
Drug: Traditional antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional antibiotic scheme administered just before, during, or after incision and continued for 5 days (Control Group, CG)
Study: 3545674
Drug: Heparin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin concentration of 5 U/ml
Study: 3545674
Drug: Heparin flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin flow rate of 1 ml/h
Study: 31886828
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin and 2% chlorhexidine‐impregnated cloths (active treatment, n = 117)
Study: 31886828
Drug: Petrolatum intranasal
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrolatum intranasal ointment and nonmedicated soap cloths (placebo, n = 119)
Study: 31886828
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin and 2% chlorhexidine‐impregnated cloths (active treatment)
Study: 18035196
Drug: Abrupt cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abrupt cessation of guanfacine ER (1 mg to 4 mg over 16 days, then placebo from days 17 to 32)
Study: 18035196
Drug: Taper-down of
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper-down of guanfacine ER (1 mg to 4 mg over 16 days, then taper down from 3 mg to placebo over 16 days)
Study: 18035196
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered daily from days 1-32)
Study: 15656812
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied three times weekly for 8 weeks, daily for 8 weeks, then daily with occlusion for 8 weeks
Study: 7261629
Drug: Clofibrate treatment
Normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofibrate treatment
Study: 27330026
Drug: Testimonial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testimonial therapy
Study: 24671501
Drug: Leining (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leining (10 mg/kg)
Study: 3841410
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg atropine
Study: 6559719
Drug: PGE2-Gel without
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2-Gel without prior treatment with Betamimetica (n = 6)
Study: 6559719
Drug: Fenoterol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (5 mb) administered 30 minutes prior to PGE2-Gel (n = 6)
Study: 6559719
Drug: Ritodrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine (10 mg) administered 30 minutes prior to PGE2-Gel (n = 6)
Study: 23864514
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration exercise (vibration amplitude: 1-3 mm; frequency: 6-26 Hz; 4-5 bouts × 60 seconds; 3-5 times weekly)
Study: 21859995
Drug: FLOX (FULV
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOX (FULV plus oxaliplatin 85 mg/m(2) IV on days 1, 15, and 29 of each cycle)
Study: 21859995
Drug: FULV (FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: FULV (FU 500 mg/m(2) by IV bolus weekly for 6 weeks; leucovorin 500 mg/m(2) IV weekly for 6 weeks of each 8-week cycle for three cycles)
Study: 15274382
Drug: 1-month intravenous
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month intravenous induction of IFN-alpha2b
Study: 7753886
Drug: Aspartame (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (400 mg) administered 60 min before meal (Group C)
Study: 7753886
Drug: Aspartame (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (400 mg) administered 30 min before meal (Group B)
Study: 23706639
Drug: Albaconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albaconazole 100 mg weekly for 24 or 36 weeks
Study: 23706639
Drug: Albaconazole 400
Normalized name: Albaconazole
DrugBank: Albaconazole (DB12073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albaconazole 400 mg weekly for 24 or 36 weeks
Study: 7936512
Drug: Depot leuprolide
Normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot leuprolide (3.75 mg/month)
Study: 2062489
Drug: Argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon laser treatment
Study: 2282940
Drug: Krypton laser
Normalized name: krypton (81mKr) gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton laser treatment
Study: 22480099
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg elemental iron once per week
Study: 22480099
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg elemental iron daily (group I)
Study: 22480099
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg elemental iron once per week (group II)
Study: 11560881
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 mg/day for 8 weeks
Study: 22133776
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 mg/day
Study: 11560881
Drug: Thalidomide doses
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide doses greater than 100 mg/day
Study: 30443999
Drug: Ticagrelor 45
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 45 mg
Study: 27038001
Drug: Ticagrelor (45,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (45, 60, and 90 mg)
Study: 27038001
Drug: Ticagrelor (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (45 and 90 mg)
Study: 14700149
Drug: Indomethacin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (3 doses at 12-hour intervals)
Study: 30849533
Drug: Follow-up phone
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up phone reminders for email administration of NDI and JOA
Study: 26630997
Drug: Contrast concentration
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast concentration of 300 mgI/mL
Study: 26630997
Drug: Contrast concentration
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast concentration of 240 mgI/mL
Study: 26630997
Drug: Contrast concentration
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast concentration of 140 mgI/mL
Study: 24947583
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 24)
Study: 16236558
Drug: Present-centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-centered therapy (comparison treatment)
Study: 16236558
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure therapy
Study: 17327524
Drug: Present-centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-centered therapy
Study: 7618707
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard transfusion therapy)
Study: 2096487
Drug: Subcutaneous DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous DDAVP (0.3 microgram/kg)
Study: 361201
Drug: CEA assay
Normalized name: Ad-CEA vaccine
DrugBank: Ad-CEA vaccine (DB17581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEA assay with levels above 9 ng/ml
Study: 361201
Drug: CEA assay
Normalized name: Ad-CEA vaccine
DrugBank: Ad-CEA vaccine (DB17581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEA assay with levels less than 9 ng/ml
Study: 30561287
Drug: Unconditional cash
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconditional cash transfers (UCT) of 10,000 XOF monthly from July to November 2013 and 2014
Study: 26090428
Drug: 7-day nonbismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day nonbismuth containing quadruple therapy (EACM)
Study: 26090428
Drug: 7-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day standard triple therapy (EAC)
Study: 24267042
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (18 g/d) and isoflavone tablets (105 mg/d isoflavone aglycone equivalents)
Study: 24267042
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein and placebo tablets
Study: 24267042
Drug: Control protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control protein and isoflavone tablets
Study: 17943674
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of VCT with conventional therapy
Study: 15476447
Drug: 131I plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I plus pretreatment with methimazole (30 mg/day)
Study: 31432392
Drug: Intravenous posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous posaconazole 300 mg (fasted)
Study: 31432392
Drug: Oral posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral posaconazole 300 mg (fasted)
Study: 31432392
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events for oral posaconazole 300 mg (high-fat breakfast)
Study: 26072311
Drug: Adherence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence therapy (AT) plus usual care
Study: 23452682
Drug: Medication at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication at follow-up (mostly stimulants)
Study: 19065416
Drug: Orbital floor
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital floor injection method (group 3)
Study: 16048152
Drug: Intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular midazolam (0.2 mg/kg)
Study: 1825100
Drug: AA-2414 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA-2414 (40 mg/day)
Study: 1825100
Drug: AA-2414 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA-2414 (20 mg/day)
Study: 31553457
Drug: Oxycodone 60
Normalized name: oxyCODONE 60 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 60 mg
Study: 27647873
Drug: Oxycodone 30
Normalized name: oxycodone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 30 mg
Study: 25196855
Drug: Non-CR after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-CR after EMR treatments
Study: 10485423
Drug: Heparin coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin coated circuits
Study: 8636371
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (ND) 300 mg/week
Study: 8636371
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 300 mg/week
Study: 1780961
Drug: Slow Infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow Infusion of Enteral Nutrients (EI)
Study: 11686218
Drug: Allopurinol 100
Normalized name: allopurinol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 100 mg twice daily
Study: 8795328
Drug: Topical lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lignocaine spray (40 mg)
Study: 8795328
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine 0.5 mg.kg‐1
Study: 7793558
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine 1.5 mg.kg‐1
Study: 6734051
Drug: Propranolol (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.05, 0.1, and 0.2 mg/kg)
Study: 6734051
Drug: Verapamil (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.1, 0.2, and 0.4 mg/kg)
Study: 31490959
Drug: LPV/r+3TC (dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r+3TC (dual therapy)
Study: 31490959
Drug: LPV/r+2NRTIs (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r+2NRTIs (triple therapy)
Study: 29297472
Drug: Hybrid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid treatment (minimally invasive direct coronary artery bypass / percutaneous coronary intervention)
Study: 29297472
Drug: Classic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classic treatment (coronary artery bypass grafting / off‑pump coronary artery bypass)
Study: 24029429
Drug: Individualized dosing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dosing of ESA guided by the Smart Anemia Manager algorithm
Study: 24029429
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol for ESA dosing
Study: 24029429
Drug: Individualized dosing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dosing of ESA
Study: 21313901
Drug: Citrullus colocynthis
Normalized name: CITRULLUS COLOCYNTHIS FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrullus colocynthis (300 mg daily for 6 weeks)
Study: 16062095
Drug: Topiramate 200
Normalized name: topiramate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 200 mg/day and 100 mg/day
Study: 7486183
Drug: Methohexital (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (3.0 mg/kg)
Study: 7486183
Drug: Thiopental (7.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (7.3 mg/kg)
Study: 24748630
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg every 4 weeks (q4wks)
Study: 24748630
Drug: Golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 100 mg every 4 weeks (q4wks)
Study: 23161902
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg or 100 mg (from week 24)
Study: 24748630
Drug: Golimumab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab (50 mg or 100 mg)
Study: 17169543
Drug: Kytta-Salbe f
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kytta-Salbe f (comfrey root extract ointment), 6g daily application (3 x 2g) for 3 weeks
Study: 9748710
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release enteric-coated test formulation containing aesculus extract, 50 mg escin b.i.d.
Study: 9748710
Drug: Prolonged-release reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release reference preparation, 50 mg escin b.i.d.
Study: 30786877
Drug: Current regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current regular drinking (at least weekly)
Study: 30786877
Drug: Heavy episodic
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy episodic drinking (> 60 g/session)
Study: 21728389
Drug: ELIOT (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELIOT (21 Gy single dose)
Study: 12782919
Drug: Continuous intestinal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intestinal levodopa infusion
Study: 12782919
Drug: Oral sustained-release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained-release levodopa preparation
Study: 10957888
Drug: Roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 150 mg 12-hourly for 10 days
Study: 10957888
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate 500 mg 6-hourly for 10 days
Study: 3535741
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin hydrochloride (450 mg/m2)
Study: 19730942
Drug: 10% Xylocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Xylocaine pump spray plus plain Strepsils
Study: 19730942
Drug: Strepsils Dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strepsils Dual Action anesthetic lozenge plus distilled water spray
Study: 15896585
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg and propofol 1 mg/kg (group 2 n = 20)
Study: 7965263
Drug: Losartan 25
Normalized name: LOSARTAN 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 25 mg
Study: 12169868
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of losartan 25 mg and enalapril 10 mg
Study: 11903415
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg b.i.d.)
Study: 7715987
Drug: CMV immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV immunoglobulin (CMVIG) 150 mg/kg
Study: 879708
Drug: Thompson endoprosthesis
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thompson endoprosthesis with intensive physical therapy
Study: 879708
Drug: Thompson endoprosthesis
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thompson endoprosthesis with routine physical therapy
Study: 879708
Drug: Internal fixation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal fixation with intensive physical therapy
Study: 19674354
Drug: Nebulized 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized 3% hypertonic saline solution and salbutamol
Study: 19674354
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (4.0 mL normal (0.9%) saline with 2.5 mg salbutamol)
Study: 15687232
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy followed by purged autologous stem-cell transplantation
Study: 15687232
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and interferon (cyclophosphamide, doxorubicin, teniposide, prednisone, and interferon)
Study: 12297768
Drug: Balloon-occluded endoscopic
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon-occluded endoscopic injection sclerotherapy (BO-EIS)
Study: 8758250
Drug: Ifosfamide (IFO)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide (IFO) administered as 6-9 g/m2 over 15 days, repeated every 3 weeks for up to 16 courses, either as a continuous 72 h infusion or as three bolus doses of 3 g/m2 on consecutive days.
Study: 8758250
Drug: Ifosfamide (IFO)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide (IFO) administration with changes in metabolism measured during early and late courses.
Study: 1883969
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (100 U/kg thrice weekly for 6 weeks, then 50 to 150 U/kg thrice weekly for 6 weeks)
Study: 30225786
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity prescription (PPA)
Study: 28887907
Drug: WBB beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBB beverage (25 g freeze dried WBB powder)